Patients who respond to EGFR-TKIs initially experience good clinical therapeutic effects, though, inevitably, after 11–13 months of treatment, some new resistance mechanisms develop as the tumor cells adapt to the treatment, which is termed “acquired resistance”. This evidence concerns the gene EGFR and neoplasm.